No need of prescription from Doctors for Refresh Tears: DTAB

Published On 2022-10-27 12:30 GMT   |   Update On 2022-10-27 12:30 GMT
No need of prescription from Doctors for Refresh Tears: DTAB
  • whatsapp icon

New Delhi: Granting drug maker Allergan India request to change the category of "Refresh Tears" from prescription drug to over the counter drug, the Drug Technical Advisory Board (DTAB) has agreed to remove the requirement of a prescription from a Registered Medical Practitioner (RMP) in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) for its retail sale.

The recommendation was made after considering the proposal made by Allergan India to remove the requirement for a prescription in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) sterile opthalmic solution for retail sale.

The drug maker, Allergen, has submitted that its product "Refresh Tears" contains Carboxymethylcellulose Sodium eye drops 0.5% w/v, sterile ophthalmic solution, indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eyes or exposure to wind or sun, and may be used as a protectant against further irritation, and stated that the product has been marketed since 1998.
The firm has also requested to change the category of this product from prescription drug to the category of non-prescription drug, i.e. "Rx to Over-The-Counter (non-prescription)".
Consequently, the firm has sought an exemption from putting the "Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only" on the labels and package inserts of "Refresh Tears" as applicable for a prescription drug.
The proposal was previously discussed at the SEC (Ophthalmology) meeting on January 28,2022, where the committee recommended that the said drug product be sold without a prescription from a Registered Medical Practitioner."Further, action may be taken as per the rules," it added.
In light of the foregoing, the Board, after detailed deliberation, agreed to the recommendation made by the Subject Expert Committee and recommended removing the requirement of a prescription from a Registered Medical Practitioner (RMP) in respect of drug products, "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) for its retail sale. Accordingly, relevant provisions of the rules may be amended.

Also Read:59 drug samples including Cadila Pharma Aciloc 150 fail to qualify CDSCO test


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News